Skip to content

Clinical registration study on the safety of Galantamine hydrobromide injection based on real world

Clinical registration study on the safety of Galantamine hydrobromide injection based on real world

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082365
Enrollment
Unknown
Registered
2024-03-27
Start date
2024-03-31
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

For myasthenia gravis, poliomyelitis sequelae, sensory and motor disorders due to diseases or injuries of the nervous system, polyneuritis and spinal neuritis, and antagonistic tubocurarine chloride and similar drugs for non-depolarizing muscle relaxations

Interventions

Galantamine hydrobromide injection standard dose group:NA

Sponsors

wenzhou peoples hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Clinically suitable for patients with galantamine hydrobromide injection; 2. Obtain the informed consent and signature of the patient or guardian

Exclusion criteria

Exclusion criteria: 1. According to the contraindications and precautions listed in the approved instruction manual for Galantamine hydrobromide injection, there are any contraindications or other circumstances that prohibit the use of Galantamine hydrobromide injection; 2, poor compliance, unable to complete or refuse to complete the interviewer; 3. Patients with mental disorders and other factors affecting compliance; 4, known allergy to the components of this drug; 5. Researchers believe that candidates are not suitable for admission

Design outcomes

Primary

MeasureTime frame
Blood routine;Liver function;Renal function;

Secondary

MeasureTime frame
Adverse event;

Countries

China

Contacts

Public ContactHuaYe

Wenzhou People's Hospital

40707729@qq.com+86 139 6880 0035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026